Fig. 2From: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialDuration of ≥35% reduction from baseline in spleen volume. Duration of spleen response was evaluated for the 92 patients in the ruxolitinib group who achieved a ≥35% reduction from baseline in spleen volume. NE, not evaluableBack to article page